TME Financial Statements From 2010 to 2026

Stocks . France . 
Stock . TME Pharma NV
ALTME Stock   0.08  0  4.63%   
Analyzing historical trends in various income statement and balance sheet accounts from TME Pharma's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting TME Pharma's valuation are summarized below:
Gross Profit
27 K
Market Capitalization
7.7 M
Enterprise Value Revenue
258.5301
Revenue
27 K
Earnings Share
(0.05)
There are currently one hundred twenty fundamental trend indicators for TME Pharma NV that can be evaluated and compared over time across competition. Investors and active traders are advised to double-check TME Pharma's current fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction.

TME Pharma Total Revenue

33,031.93

Check TME Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TME Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 14.5 K, Interest Expense of 549.5 K or Selling General Administrative of 1.6 M, as well as many indicators such as Price To Sales Ratio of 92.3, Dividend Yield of 0.0 or PTB Ratio of 1.2. TME financial statements analysis is a perfect complement when working with TME Pharma Valuation or Volatility modules.
  
This module can also supplement various TME Pharma Technical models . Check out the analysis of TME Pharma Correlation against competitors.

TME Pharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets5.1 M3.9 M4.2 M
Slightly volatile
Short and Long Term Debt Total47.9 K50.4 K3.5 M
Slightly volatile
Other Current Liabilities218.6 K369 K333.3 K
Slightly volatile
Total Current Liabilities1.5 M1.6 M4.4 M
Slightly volatile
Other Liabilities8559001.9 K
Slightly volatile
Property Plant And Equipment Net29.9 K31.5 K314.8 K
Slightly volatile
Current Deferred Revenue700.3 K402.3 K716.4 K
Very volatile
Accounts Payable1.4 M1.2 M1.9 M
Slightly volatile
Cash4.4 M3.7 M3.4 M
Slightly volatile
Non Current Assets Total36.8 K38.7 K399 K
Slightly volatile
Cash And Short Term Investments4.4 M3.7 M3.4 M
Slightly volatile
Net Receivables22.2 K23.4 K139.3 K
Very volatile
Common Stock Total Equity515.7 K542.8 K1.2 M
Very volatile
Common Stock Shares Outstanding33 M31.5 M5.8 M
Slightly volatile
Liabilities And Stockholders Equity5.1 M3.9 M4.2 M
Slightly volatile
Other Current Assets78.7 K82.8 K271.4 K
Slightly volatile
Other Stockholder Equity166 M230.9 M143.5 M
Slightly volatile
Total Liabilities1.5 M1.6 M6.1 M
Slightly volatile
Long Term Investments4.3 K4.5 K50.2 K
Slightly volatile
Property Plant And Equipment Gross249.4 K292.5 K415.2 K
Slightly volatile
Total Current Assets4.8 M3.9 M3.8 M
Slightly volatile
Short Term Debt47.9 K50.4 K1.6 M
Slightly volatile
Intangible Assets3.4 K3.6 K31.9 K
Slightly volatile
Common Stock1.4 M847.8 K1.4 M
Very volatile
Property Plant Equipment29.1 K30.6 K314.5 K
Slightly volatile
Capital Surpluse177.8 M231.1 M153.6 M
Slightly volatile
Cash And Equivalents4.7 M3.7 M3.5 M
Slightly volatile
Capital Stock1.6 M847.8 K5.8 M
Slightly volatile

TME Pharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization14.5 K15.3 K134.5 K
Slightly volatile
Interest Expense549.5 K578.5 K1.7 M
Pretty Stable
Selling General Administrative1.6 M2.7 M1.9 M
Pretty Stable
Selling And Marketing Expenses203.5 K129.6 K180.3 K
Pretty Stable
Other Operating Expenses6.6 M4.7 M9.1 M
Slightly volatile
Research Development3.3 M2.6 M2.6 M
Slightly volatile
Cost Of Revenue66.7 K70.2 K1.5 M
Slightly volatile
Total Operating Expenses5.8 M4.7 M7.6 M
Slightly volatile
Interest Income35 K36.8 K530.8 K
Pretty Stable
Reconciled Depreciation74.5 K89.7 K53.5 K
Slightly volatile

TME Pharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow4.6 M2.6 M4.3 M
Very volatile
Depreciation100.3 K70.2 K156.8 K
Slightly volatile
Capital Expenditures15.4 K14.4 K25.3 K
Slightly volatile
Total Cash From Financing Activities6.2 M5.1 M7.8 M
Slightly volatile
End Period Cash Flow4.4 M3.7 M3.4 M
Slightly volatile
Issuance Of Capital Stock5.1 M8.4 M4.8 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio92.397.1635.9 K
Pretty Stable
Days Sales Outstanding54657479.5 K
Very volatile
Capex To Depreciation0.180.20510.2058
Pretty Stable
Payables Turnover0.06430.06760.707
Slightly volatile
Sales General And Administrative To Revenue1341412.6 K
Pretty Stable
Research And Ddevelopement To Revenue1031097.2 K
Pretty Stable
Capex To Revenue0.720.7678.6416
Pretty Stable
Cash Per Share0.130.1474.2872
Slightly volatile
Days Payables Outstanding2.8 K2.7 K2.6 K
Slightly volatile
Income Quality1.250.931.0777
Very volatile
Intangibles To Total Assets0.00130.00140.01
Slightly volatile
Current Ratio0.871.690.9508
Slightly volatile
Receivables Turnover0.690.660.2245
Slightly volatile
Capex Per Share6.0E-47.0E-41.0816
Slightly volatile
Revenue Per Share8.0E-48.0E-41.7065
Slightly volatile
Interest Debt Per Share0.02230.0235246
Slightly volatile
Debt To Assets0.0180.01891.0742
Slightly volatile
Operating Cycle42745054.3 K
Pretty Stable
Days Of Payables Outstanding2.8 K2.7 K2.6 K
Slightly volatile
Ebt Per Ebit1.361.251.2018
Pretty Stable
Quick Ratio0.861.690.9415
Slightly volatile
Net Income Per E B T0.80.90.9825
Slightly volatile
Cash Ratio1.711.630.9224
Slightly volatile
Days Of Sales Outstanding54657479.5 K
Very volatile
Free Cash Flow Operating Cash Flow Ratio0.80.90.985
Slightly volatile
Fixed Asset Turnover0.940.620.5599
Very volatile
Debt Ratio0.0180.01891.0742
Slightly volatile
Price Sales Ratio92.397.1635.9 K
Pretty Stable
Asset Turnover0.00610.00640.0214
Very volatile

TME Pharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap12.3 M13.9 M15.1 M
Slightly volatile
Enterprise Value6.7 M7.6 M8.3 M
Slightly volatile

TME Fundamental Market Drivers

Forward Price Earnings1.0715
Cash And Short Term Investments3.2 M

About TME Pharma Financial Statements

TME Pharma shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although TME Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in TME Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on TME Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue402.3 K700.3 K
Total Revenue17.1 K33 K
Cost Of Revenue70.2 K66.7 K
Stock Based Compensation To Revenue 14.78  14.04 
Sales General And Administrative To Revenue 141.21  134.14 
Research And Ddevelopement To Revenue 108.76  103.32 
Capex To Revenue 0.76  0.72 
Ebit Per Revenue(319.40)(335.37)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill

Additional Tools for TME Stock Analysis

When running TME Pharma's price analysis, check to measure TME Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TME Pharma is operating at the current time. Most of TME Pharma's value examination focuses on studying past and present price action to predict the probability of TME Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TME Pharma's price. Additionally, you may evaluate how the addition of TME Pharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY